Key Details
Price
$133.50Annual Revenue
$4.50 BAnnual EPS
-$7.34Annual ROE
-18.81%Beta
1.16Events Calendar
Next earnings date:
Feb 07, 2025Recent quarterly earnings:
Nov 04, 2024Recent annual earnings:
Feb 08, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
June 25, 2024Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
This focus on the ROBO Global Healthcare Technology and Innovation Index showcases Grail (GRAL), which is a notable player in the Genomics subsector. Grail is an important part of the $53.6 million ROBO Global Healthcare Technology and Innovation ETF (HTEC).
Synaffix B.V., a company under Lonza, has announced a licensing agreement with Illumina, a leader in DNA sequencing technologies. This agreement allows Illumina to use Synaffix's patent portfolio related to metal-free click chemistry in its next-generation sequencing products. The goal is to enhance the development of antibody-drug conjugates with improved therapeutic effectiveness.
Illumina, Inc. (NASDAQ:ILMN) will participate in the Evercore ISI HealthCONx Healthcare Conference on December 3, 2024, at 9:00 AM ET. The company will be represented by Ankur Dhingra, the CFO, and Sallilyn Schwartz, the VP of Investor Relations. Vijay Kumar from Evercore ISI will also be part of the conference call.
Illumina, Inc. (NASDAQ:ILMN) will participate in the Wolfe Research 2024 Healthcare Conference Call on November 20, 2024, at 9:20 AM ET. The company's Chief Financial Officer, Ankur Dhingra, will be present, along with Doug Schenkel from Wolfe Research. Doug Schenkel begins the call by greeting everyone.
At the annual meeting of the Association of Molecular Pathology, the newest method for detailed genomic profiling of tumors will be showcased. Illumina, Inc., a leader in DNA sequencing, has announced the upcoming launch of TruSight™ Oncology 500 v2, an updated version of its main cancer research tool designed for comprehensive genomic profiling. This new assay is still in development and is expected to be available worldwide by mid-2025.
No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.
Illumina is the top company in the Next Generation Sequencing market. The sale of Grail has allowed for increased profit margins and stronger cash flow. However, the stock fell after hours because much of the positive news was already reflected in the recent price increase.
Illumina's revenues from its consumables sector in the third quarter have shown strong growth, but this is balanced out by a decrease in the instruments sector.
Illumina (ILMN) reported quarterly earnings of $1.14 per share, which is higher than the Zacks Consensus Estimate of $0.87 per share. This is an increase compared to earnings of $0.33 per share from the same period last year.
Illumina (ILMN) is experiencing a drop in its stock price, predicting a 3% decrease in revenue. However, George Tsilis thinks the company remains significant, regardless of how the market is responding.
FAQ
- What is the primary business of Illumina?
- What is the ticker symbol for Illumina?
- Does Illumina pay dividends?
- What sector is Illumina in?
- What industry is Illumina in?
- What country is Illumina based in?
- When did Illumina go public?
- Is Illumina in the S&P 500?
- Is Illumina in the NASDAQ 100?
- Is Illumina in the Dow Jones?
- When was Illumina's last earnings report?
- When does Illumina report earnings?
- Should I buy Illumina stock now?